SCHEMBL20945667

SCHEMBL20945667

CCOC(=O)CCC(=O)c1cc(F)cc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 3/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
STING1 Q86WV6 2/20 0.40
TSHR P16473 2/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
HPGD P15428 1/20 0.39
NR1I2 O75469 1/20 0.39
PGR P06401 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13612883 0.91 ALDH1A1 (0.45) LMNANPC1ALDH1A1KMT2AMEN1
SCHEMBL979632 0.90 NPC1 (0.47) NPC1ALDH1A1KMT2AMEN1KDM4E
SCHEMBL30666368 0.88 SMN1; SMN2 (0.49) LMNANPC1ALDH1A1KMT2AMEN1
SCHEMBL2459005 0.84 MEN1 (0.59) LMNANPC1ALDH1A1KMT2AMEN1
SCHEMBL5313798 0.84 NPC1 (0.57) LMNANPC1ALDH1A1KMT2AMEN1
SCHEMBL1376927 0.83 SMN1; SMN2 (0.44) LMNAALDH1A1KMT2AMEN1KDM4E
SCHEMBL4686898 0.83 LMNA (0.61) LMNANPC1ALDH1A1KMT2AMEN1
SCHEMBL31478419 0.82 TSHR (0.48) LMNAALDH1A1KMT2AMEN1KDM4E
SCHEMBL4315127 0.82 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL1376585 0.81 MEN1 (0.52) LMNAALDH1A1KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12338241-B2 Bicyclic sulfones and sulfoxides and methods of use thereof GENENTECH, INC. (US) 2025-06-24 US disclosed
CN-111278809-B Bicyclic sulfones and sulfoxides, and methods of use thereof 豪夫迈·罗氏有限公司 2024-06-25 CN disclosed
EP-3704097-B1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF HOFFMANN LA ROCHE (CH) 2023-10-25 EP disclosed
US-20230002391-A1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2023-01-05 US disclosed
US-11072617-B2 Bicyclic sulfones and sulfoxides and methods of use thereof GENENTECH, INC. (US) 2021-07-27 US disclosed
EP-3704097-A1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2020-09-09 EP disclosed
CN-111278809-A Bicyclic sulfones and sulfoxides, and methods of use thereof 豪夫迈·罗氏有限公司 2020-06-12 CN disclosed
US-20190127382-A1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11072617-B2 Bicyclic sulfones and sulfoxides and methods of use thereof RB1, CCNE2, RPS3A LMNA 2336/4885NPC1 3740/4885ALDH1A1 1912/4885
US-20190127382-A1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF RB1, CCNE2, RPS3A LMNA 2336/4885NPC1 3740/4885ALDH1A1 1912/4885
US-12338241-B2 Bicyclic sulfones and sulfoxides and methods of use thereof RB1, CCNE2, RPS3A LMNA 2336/4885NPC1 3740/4885ALDH1A1 1912/4885
US-20230002391-A1 BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOF RB1, CCNE2, RPS3A LMNA 2336/4885NPC1 3740/4885ALDH1A1 1912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.